Schizophrenia Trial of Aripiprazole

Phase 3

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Aripiprazole; Drug: Olanzapine or Quetiapine or Risperidone

• Registration Number: NCT00237913
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07
• Primary Completion: 2005-08
• Study Completion: 2005-08
• Study First Submitted: 2005-10-11
• Study First Submitted QC: 2005-10-11
• Study First Posted: 2005-10-13
• Status Verified: 2008-07
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

• Clinical diagnosis of schizophrenia
• Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated

Exclusion Criteria

• Diagnosis of schizoaffective disorder
• Patients treatment-resistant to antipsychotics

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A1	Aripiprazole	-
B1	Olanzapine or Quetiapine or Risperidone	-

Primary Outcome Measures

Name	Time	Method
Score on the Investigator Assessment Questionnaire at week 26

Secondary Outcome Measures

Name	Time	Method
Clinical Global Impression scale and patient preference of medication at endpoint

Trial Locations

Locations (1)

Local Institution; 🇬🇧 Birmingham, West Midlands, United Kingdom